Cargando…

Validation of the Erlangen Score Algorithm for Differential Dementia Diagnosis in Autopsy-Confirmed Subjects

BACKGROUND: Despite decades of research on the optimization of the diagnosis of Alzheimer’s disease (AD), its biomarker-based diagnosis is being hampered by the lack of comparability of raw biomarker data. In order to overcome this limitation, the Erlangen Score (ES), among other approaches, was set...

Descripción completa

Detalles Bibliográficos
Autores principales:	Somers, Charisse, Lewczuk, Piotr, Sieben, Anne, Van Broeckhoven, Christine, De Deyn, Peter Paul, Kornhuber, Johannes, Martin, Jean-Jacques, Bjerke, Maria, Engelborghs, Sebastiaan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484252/ https://www.ncbi.nlm.nih.gov/pubmed/30883344 http://dx.doi.org/10.3233/JAD-180563

Ejemplares similares

Reconceptualization of the Erlangen Score for the Assessment of Dementia Risk: The ERlangen Score
por: Utz, Janine, et al.
Publicado: (2023)

Added Diagnostic Value of Cerebrospinal Fluid Biomarkers for Differential Dementia Diagnosis in an Autopsy-Confirmed Cohort
por: Niemantsverdriet, Ellis, et al.
Publicado: (2018)

Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer’s disease
por: Baldeiras, Inês, et al.
Publicado: (2019)

No added diagnostic value of non-phosphorylated tau fraction (p-tau(rel)) in CSF as a biomarker for differential dementia diagnosis
por: Goossens, Joery, et al.
Publicado: (2017)

The Use of Biomarkers and Genetic Screening to Diagnose Frontotemporal Dementia: Evidence and Clinical Implications
por: Gossye, Helena, et al.
Publicado: (2019)

Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and (18)F-FDG-PET imaging
por: Ottoy, Julie, et al.
Publicado: (2019)

Le programme d'Erlangen
por: Klein, Felix
Publicado: (1974)

Amyloid-β(1–43) cerebrospinal fluid levels and the interpretation of APP, PSEN1 and PSEN2 mutations
por: Perrone, Federica, et al.
Publicado: (2020)

The genetics and neuropathology of frontotemporal lobar degeneration
por: Sieben, Anne, et al.
Publicado: (2012)

Diagnostic value of cerebrospinal fluid tau, neurofilament, and progranulin in definite frontotemporal lobar degeneration
por: Goossens, Joery, et al.
Publicado: (2018)

Risk analysis for radiotherapy at the Universitätsklinikum Erlangen
por: Lohmann, Daniel, et al.
Publicado: (2022)

Improved Alzheimer’s Disease versus Frontotemporal Lobar Degeneration Differential Diagnosis Combining EEG and Neurochemical Biomarkers: A Pilot Study
por: Laton, Jorne, et al.
Publicado: (2022)

The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer’s disease
por: Vermeiren, Yannick, et al.
Publicado: (2015)

Contribution of rare homozygous and compound heterozygous VPS13C missense mutations to dementia with Lewy bodies and Parkinson’s disease
por: Smolders, Stefanie, et al.
Publicado: (2021)

Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer’s Disease Diagnosis
por: Bjerke, Maria, et al.
Publicado: (2018)

Cerebrospinal Fluid P-Tau(181P): Biomarker for Improved Differential Dementia Diagnosis
por: Struyfs, Hanne, et al.
Publicado: (2015)

Validation of the Erlangen Test of Activities of Daily Living in Persons with Mild Dementia or Mild Cognitive Impairment (ETAM)
por: Luttenberger, Katharina, et al.
Publicado: (2016)

Diagnostic value of MIBG cardiac scintigraphy for differential dementia diagnosis
por: Slaets, Sylvie, et al.
Publicado: (2015)

The Erlangen test of activities of daily living in persons with mild dementia or mild cognitive impairment (ETAM) – an extended validation
por: Book, Stephanie, et al.
Publicado: (2018)

The Cerebrospinal Fluid Aβ(1–42)/Aβ(1–40) Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer’s Disease in a Clinical Setting
por: Niemantsverdriet, Ellis, et al.
Publicado: (2017)

Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort
por: Gijselinck, Ilse, et al.
Publicado: (2015)

An intronic VNTR affects splicing of ABCA7 and increases risk of Alzheimer’s disease
por: De Roeck, Arne, et al.
Publicado: (2018)

Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer’s dementia?
por: Crum, Jana, et al.
Publicado: (2018)

Factors Associated with Pneumonia-caused Death in Older Adults with Autopsy-confirmed Dementia
por: Manabe, Toshie, et al.
Publicado: (2017)

Report on a Visit to Max Planck-Institute, Munich, and Siemens Erlangen
por: Tallgren, U
Publicado: (1961)

Account of Professor Reich of Erlangen's Treatment of Febrile Diseases with Mineral Acids
Publicado: (1801)

Cerebrospinal fluid and serum MHPG improve Alzheimer's disease versus dementia with Lewy bodies differential diagnosis
por: Janssens, Jana, et al.
Publicado: (2018)

Patients carrying the mutation p.R406W in MAPT present with non-conforming phenotypic spectrum
por: Gossye, Helena, et al.
Publicado: (2022)

Alzheimer’s disease CSF biomarkers: clinical indications and rational use
por: Niemantsverdriet, Ellis, et al.
Publicado: (2017)

Investigating the role of filamin C in Belgian patients with frontotemporal dementia linked to GRN deficiency in FTLD-TDP brains
por: Janssens, Jonathan, et al.
Publicado: (2015)

Serum Daytime Melatonin Levels Reflect Cerebrospinal Fluid Melatonin Levels in Alzheimer’s Disease but Are Not Correlated with Cognitive Decline
por: Nous, Amber, et al.
Publicado: (2021)

Séminaire Lotharingien de Combinatoire : Bayreuth, Erlangen, Strasbourg : 21e Session
por: Berker, A N
Publicado: (1990)

Cerebrospinal fluid inflammatory biomarkers for disease progression in Alzheimer’s disease and multiple sclerosis: a systematic review
por: Temmerman, Joke, et al.
Publicado: (2023)

Long-Term Exercise and Risk of Metabolic and Cardiac Diseases: The Erlangen Fitness and Prevention Study
por: Kemmler, Wolfgang, et al.
Publicado: (2013)

Combined Analysis of CSF Tau, Aβ42, Aβ1–42% and Aβ1–40(ox)% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia
por: Bibl, Mirko, et al.
Publicado: (2010)

Clinico‐pathological comparison of patients with autopsy‐confirmed Alzheimer's disease, dementia with Lewy bodies, and mixed pathology
por: Chatterjee, Atri, et al.
Publicado: (2021)

Depressive Symptoms in the Elderly—An Early Symptom of Dementia? A Systematic Review
por: Wiels, Wietse, et al.
Publicado: (2020)

Extended FTLD pedigree segregating a Belgian GRN-null mutation: neuropathological heterogeneity in one family
por: Sieben, Anne, et al.
Publicado: (2018)

Interprofessional education in Erlangen: A needs analysis and the conceptual work of a student working group
por: Konietzko, Raffael, et al.
Publicado: (2016)

15th European Workshop for Rheumatology Research: Erlangen/Bamberg, March 16–19, 1995
Publicado: (1995)

Cannot write session to /tmp/vufind_sessions/sess_dhpaceklkbhkiula3ev2p6b4h9